Journals / Turkish Neurosurgery / 2009 / Cilt: 19 - Sayı: 4

Deneysel tavşan subaraknoid kanama modelinde intravenöz cilostazol ve nimodipine etkilerinin araştırılması

The effects of tntravenous cilostazol and nimodipine on cerebral vasospasm after subarachnoid hemorrhage in an experimental rabbit model

Pages
374–379
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Our results demonstrate that intravenous administration of both cilostazol and nimodipine significantly attenuates cerebral vasospasm after SAH.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model.
📊
Key Findings & Data:MATERIAL and METHODS: Twenty-five male New Zealand White rabbits were assigned randomly to 1 of 5 groups.
💡
Conclusion & Impact:CONCLUSION: Our results demonstrate that intravenous administration of both cilostazol and nimodipine significantly attenuates cerebral vasospasm after SAH.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIM: Our aim in this study was to investigate the efficacy of intravenous administration of cilostazol and compare these effects with intravenous usage of nimodipine in subarachnoid hemorrhage model. MATERIAL and METHODS: Twenty-five male New Zealand White rabbits were assigned randomly to 1 of 5 groups. Animals in group 1 (n=5) served as controls, group 2 (n=5) was the SAH-only group, group 3 (n=5) was treated with intravenous 10 mg/kg cilostazol, group 4 (n=5) was treated with 0.05 mg/kg intravenous nimodipine, and group 5 (n=5) served as the vehicle group and treated with a mixture of dimethyl sulfoxide and phosphate buffer solution. Basilar arteries were removed from the brain stems and analyzed. The vessels were measured using computer-assisted morphometry (SPOT for Windows Version 4.1). Statistical comparisons were performed using the Kruskall-Wallis and Mann-Whitney U tests. RESULTS: Basilar artery wall thicknesses in group 3 and 4 were smaller than the group 2 and this was statistically significant at p<0.05. The mean arterial cross-sectional areas in group 3 and 4 were higher than group 2 and this was also statistically significant at p<0.05. CONCLUSION: Our results demonstrate that intravenous administration of both cilostazol and nimodipine significantly attenuates cerebral vasospasm after SAH.

Özet

AMAÇ: Bu çalışmada, biz subaraknoid kanamada intravenöz olarak uygulanan cilostazolün etkisini incelemeyi ve yine bu ilacın etkilerini intravenöz olarak kullanılan nimodipin ile karşılaştırmayı amaçladık. YÖNTEM ve GEREÇ: 25 adet erkek Yeni Zelanda beyaz tavşanı kullanıldı ve hayvanlar 5 gruba ayrıldı. Grup 1 (n=5) kontrol, grup 2 (n=5) sadece SAK grubu, grup 3 (n=5) SAK sonrası intravenöz 10 mg/kg cilostazol uygulanan grup ve grup 4 (n=5) SAK sonrası 0.05 mg/kg intravenöz nimodipin alan grup ve grup 5 (n=5) dimetil sülfoksit ve fosfat buffer solüsyonu karışımı uygulanan taşıyıcı grup olarak belirlendi. Baziller arterler beyin sapından ayrılarak analiz edildi. Damar ölçümleri bilgisayar programı kullanılarak (Windows versiyon 4.1 SPOT) yapıldı. İstatistiksel analizde Kruskall-Wallis ve Mann- Whitney U testleri kullanıldı. BULGULAR: Baziller arter damar kalınlığı grup 3 ve 4’te grup 2’ye göre daha küçük olarak bulundu ve bu istatistiksel olarak anlamlı idi p<0.05. Ortalama damar alanı ise grup 3 ve 4’te grup 2’den daha yüksek bulundu ve bu da istatistiksel olarak anlamlı idi p<0.05. SONUÇ: Elde edilen sonuçlara bakıldığında hem cilostazolün hemde nimodipin’in intravenöz kullanımı, SAK sonrasında gelişen serebral vazospazm da etkili bulundu.

🔖

Cite This Article

BİLGİNER, B., ÖNAL, M. B., NARİN, F., SÖYLEMEZOĞLU, F., ZİYAL, İ. M., ÖZGEN, T. (2009). Deneysel tavşan subaraknoid kanama modelinde intravenöz cilostazol ve nimodipine etkilerinin araştırılması. Turkish Neurosurgery, Cilt: 19 - Sayı: 4, 374–379. https://ajindex.com/articles/405188

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Bilginer B, Onal B, Yigitkanli K, Soylemezoglu F, Bavbek M, Ziyal I.M, Ozgen T: Treatment of cerebral vasospasm with cilostazol in subarachnoid haemorrhage model. Acta Neurochir Suppl 104: 291-296,2008 2. Birk S, Edvinsson L, Olesen J, Kruuse C: Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol 489(1-2):93-100,2004 3. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J: The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24(12):1352-1358,2004 4. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW: Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300(3):787- 793,2002 5. Chow M, Dumont AS, Kassell NF: Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 51(6):1333-1341,2002 6. Clark J, Sharp F: Bilirubin oxidation products (BOXes) and their role in cerebral vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 26:1223-1233,2006 7. Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schütt S, Fritzinger M, Horn P, Vajkoczy P, Kreisel S, Brunner J, Schmiedek P, Hennerici M: Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry 70(4):534- 537,2001 8. Firat MM, Gelebek V, Orer HS, Belen D, Firat AK, Balkanci F: Selective intraarterial nimodipine treatment in an experimental subarachnoid hemorrhage model. AJNR Am J Neuroradiol 26(6):1357-1362,2005 9. Hänggi D, Turowski B, Beseoglu K, Yong M, Steiger HJ: Intraarterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: Influence on clinical course and cerebral perfusion. AJNR Am J Neuroradiol 29(6):1053-1060,2008 10. Hashimoto A, Miyakoda G, Hirose Y, Mori T: Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 189(2):350-357,2006 11. Ito H, Miyakoda G, Mori T: Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation. Platelets 15(5):293-301,2004 12. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F: Cilostazol as a unic antithrombotic agent. Curr Pharm Des 9: 2289- 2302,2003 13. Kassell NF, Sasaki T, Colahan AR, Nazar G: Cerebral vasospasm